Johnson Johnson JNJ Secures FDA Priority Review for IMAAVY Targeting FirstofItsKind Indication for Warm Autoimmune Hemolytic Anemia KODK Eastman reports Q4 2025 negative EPS of 123 dollars shares dip 062 amid sparse operational guidance US ExecutiveMedia Relations Shift Trump Ends White House Correspondents Dinner Boycott